{"denoms":[{"counts":[{"groupId":"BG000","value":"26"}],"units":"Participants"}],"groups":[{"description":"Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression\n\nIntervention: Drug: melphalan 5mg/m\\^2 orally days 1-4 every 28 days until progression\n\nIntervention: Drug: prednisone 60mg/m\\^2, orally days 1-4 every 28 days until progression","id":"BG000","title":"Treatment (Lenalidomide, Melphalan, Prednisone)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"64","upperLimit":"87","value":"73.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"17"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"I - Low Cell Mass"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"II - Intermediate Cell Mass"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"III - High Cell Mass"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"unknown"}],"paramType":"NUMBER","title":"Durie-Salmon Stage at Diagnosis","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"No"}],"paramType":"NUMBER","title":"Parameter of Hematologic Response - Serum M-spike >= 1g/dL","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"No"}],"paramType":"NUMBER","title":"Parameter of Hematologic Response - Serum Immunoglobulin Free Light Chain >= 10mg/dL","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"No"}],"paramType":"NUMBER","title":"Parameter of Hematologic Response - Urine M-spike >= 200 mg/24 hours","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"title":"No"}],"paramType":"NUMBER","title":"Parameter of Hematologic Response - None (non-secretory myeloma, bone marrow only)","unitOfMeasure":"participants"}]}